Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pitfalls of SARS-CoV-2 antigen testing at emergency department.
Cottone E, Van Hoecke F, Martens GA, De Laere E, De Smedt R, Vervaeke S, Vanhee M, De Smet D. Cottone E, et al. Among authors: de smedt r. Infect Dis (Lond). 2022 Oct;54(10):731-737. doi: 10.1080/23744235.2022.2083226. Epub 2022 May 30. Infect Dis (Lond). 2022. PMID: 35638185
Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih HJ, Reekmans A, Brown LM, Van Roy N, Palhais B, Roels J, Van der Linden M, Van Dorpe J, Ntziachristos P, Van Delft FW, Mansour MR, Pieters T, Lammens T, De Moerloose B, De Bock CE, Goossens S, Van Vlierberghe P. De Coninck S, et al. Among authors: de smedt r. Haematologica. 2024 May 1;109(5):1373-1384. doi: 10.3324/haematol.2023.283981. Haematologica. 2024. PMID: 37941480 Free article.
Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.
Provez L, Putteman T, Landfors M, Roels J, Reunes L, T'Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Maćkowska-Maślak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P. Provez L, et al. Among authors: de smedt r. Cancers (Basel). 2023 Jan 20;15(3):647. doi: 10.3390/cancers15030647. Cancers (Basel). 2023. PMID: 36765607 Free PMC article.
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B, Van Loocke W, Almeida A, Cheung LC, Kotecha RS, Mansour MR, Uyttebroeck A, Vandenberghe P, La Starza R, Mecucci C, Lammens T, Van Roy N, De Moerloose B, Barata JT, Taghon T, Goossens S, Van Vlierberghe P. De Smedt R, et al. Blood. 2020 May 7;135(19):1685-1695. doi: 10.1182/blood.2019003880. Blood. 2020. PMID: 32315407 Free article.
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P. De Smedt R, et al. Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076176 Free PMC article. No abstract available.
22 results